DOI: https://doi.org/10.36347/sajb.2025.v13i10.006

Pages: 1450-1458

Chemotherapy leads to diverse symptoms and conditions affecting the quality of life (QoL). This study examines Quality of life and pain in chemotherapy patients. Poor pain management significantly impacts patients, hindering therapy tolerance and overall, well-being. A cross-sectional observational study was conducted on 327 patients undergoing chemotherapy. Study participants were enrolled based on the inclusion and exclusion criteria. The data was collected in a self-designed data collection form, EORTC QLQ C-30 Version 3.0 standard questionnaire was used for the assessment of quality of life (QOL) and numerical pain rating scale was used to assess the severity of pain. In this study females (62.4 %) participants were more than males (37.6%). Majority of n study population were at the age group was 51-60 years. In the QOL the Functional Scale indicates high Cognitive Functioning (good QOL=84.4%, poor QOL=15.6%), but lower scores for Social (good QOL=63.3%, poor QOL=36.7%) and Physical Functioning (good QOL=63.3%, poor QOL=36.7%). On the Symptoms Scale, significant issues included Fatigue (good QOL=41.6%, poor QOL=58.4%) and Pain (good QOL=38.8%, poor QOL=61.2%), with Nausea/Vomiting affecting (good QOL= 68.5%, poor QOL=31.5%). Females (71%) reported a good quality of life (QOL) compared to males. Majority of participants did not experience pain. The main chemotherapy drugs used was carboplatin and dexamethasone was extensively used for pain management. The study highlights the role of early detection, medication adherence, and lifestyle modification in cancer management. Enhancing HRQOL in chemotherapy patients requires joint efforts from healthcare providers, patients, and support systems.